Home > Journals > Minerva Gastroenterology > Past Issues > Articles online first > Minerva Gastroenterology 2021 May 10

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Gastroenterology 2021 May 10

DOI: 10.23736/S2724-5985.21.02875-8

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Impact of Direct-Acting Antivirals (daas) on cardiovascular diseases in patients with chronic hepatitis C

Grazia PENNISI 1 , Federica SPATOLA 1, Lorenza DI MARCO 2, Vincenzo DI MARTINO 1, Vito DI MARCO 1

1 Section of Gastroenterology and Hepatology, Dipartimento Di Promozione Della Salute, Materno Infantile, Medicina Interna e Specialistica Di Eccellenza (PROMISE), University of Palermo, Palermo, Italy; 2 Gastroenterology Unit, Department of Medical Specialties, University of Modena & Reggio Emilia, Modena, Italy


PDF


In the last years the hepatitis C virus (HCV) infection was a relevant public health problem due to the large number of affected people worldwide and the impact on hepatic and extrahepatic complications. The availability of direct-acting antivirals (DAAs) and the very high rate of sustained virological response (SVR) after treatment has radically changed the course of HCV chronic infection. Robust evidence showed a close link between HCV infection and development of cardiovascular disease (CVD), as result of the atherogenic effect of the virus. This review aims to explore the evidence linking HCV infection with cardiovascular disease and to evaluate the impact of SVR after DAAs on cardiovascular complications.


KEY WORDS: HCV, chronic C hepatitis; CVD, cardiovascular diseases; DAAs, direct antiviral agents

top of page